Clinical trials: Chemoradiotherapy
Gastric Cancer
Safety and Efficacy of Sintilimab in Combination With Chemoradiothrapy Followed by D2 Surgical Resection in Patients With Advanced Gastric Cancer With Retroperitoneal Lymph Node Metastasis
Gastric cancer with retroperitoneal lymph node metastasis was considered as unresectable, to improve these patients' prognosis, we designed systematic conversion therapy including immunotherapy and chemoradiotherapy.
- Trial name
- NCT05002686
- Testing
- Sintilimab, Albumin-Paclitaxel, Capecitabine
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Ruijin Hospital
Radiotherapy
Chemoradiotherapy After Surgery Versus Preoperative Chemoradiotherapy for Stage II/III Mid-low Rectal Cancer With or Without High-risk Factors
The purpose of this observational study is to understand the effect of different timing of chemoradiotherapy on overall survival in patients with stage II/III low- and medium-level rectal cancer with or without high-risk factors
- Trial name
- NCT06566222
- Testing
- chemoradiotherapy after surgery, High-risk Factors
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Changhai Hospital
Nasopharyngeal Carcinoma
Combination of Cisplatin Plus Gemcitabine Induction Chemotherapy and Intensity-modulated radiotherapyIntensity-modulated Radiotherapy With or Without Concurrent Cisplatin for NPC
Concurrent cisplatin-based chemotherapy plus radiotherapy increased the risk of treatment-related death and severe acute toxicity.
- Trial name
- NPC (NCT01854203)
- Testing
- Inductive chemotherapy + concurrent cisplatin and IMRT, Inductive chemotherapy + IMRT
- Where
- 2 sites in China
- Volunteers
- 300 people
- Sponsor
- Sun Yat-sen University
Oesophageal Cancer
A Feasibility Study of Chemo-radiotherapy to Treat Operable Oesophageal Cancer
About 7500 patients are diagnosed with oesophageal cancer each year in the UK of which less than a quarter have resectable disease at diagnosis.
- Trial name
- NeoSCOPE (NCT01843829)
- Testing
- Oxaliplatin, Capecitabine, Carboplatin
- Where
- 12 sites in United Kingdom
- Volunteers
- 85 people
- Sponsor
- Lisette Nixon
Rectal Cancer
Oxaliplatin and 5-FU Based Preoperative Chemoradiation
Oxaliplatin and 5FU based preoperative chemoradiation in rectal cancer.
- Trial name
- LARC-RRP (NCT00278694)
- Testing
- Oxaliplatin, Chemoradiation, 5-FU
- Where
- Norway
- Volunteers
- 109 people
- Sponsor
- Oslo University Hospital
Esophageal Squamous Cell Cancer
Retlirafusp Alfa Combined With Chemoradiotherapy in Unresectable ESCC
The goal of this clinical trial is to evaluate the efficacy and safety of retlirafusp alfa combined with radical chemoradiotherapy in the treatment of locally advanced unresectable esophageal squamous cell carcinoma.
- Trial name
- NCT07769866
- Testing
- Induction chemo-immunotherapy, Concurrent chemoradiotherapy (cCRT), maintenance immunotherapy
- Where
- China
- Volunteers
- 68 people
- Sponsor
- RenJi Hospital
Carcinoma, Squamous Cell, Head and Neck Neoplasms
Monitoring of Oral Human Papillomavirus Infection (HPV) in HPV-positive Oropharyngeal Squamous Cell Carcinoma (OPSCC)
The purpose of this research study is to determine whether and when patients with human papilloma virus positive squamous cell cancer of the oropharynx treated with radiation and chemotherapy clear their human papilloma virus…
- Conditions
- Carcinoma, Squamous Cell, Head and Neck Neoplasms, Oropharyngeal Neoplasms
- Trial name
- NCT02045186
- Testing
- Assessment of Oral HPV Infection
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Stage III NSCLC
Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment
A Phase Ib, Open-label, Single-center study to assess the safety of cancer-immunotherapy induction with Tremelimumab and Durvalumab prior to Chemoradiotherapy in the treatment of locally advanced NSCLC.
- Trial name
- Induction (NCT04287894)
- Testing
- Durvalumab, Tremelimumab, Pemetrexed
- Where
- Netherlands
- Volunteers
- 18 people
- Sponsor
- The Netherlands Cancer Institute
Esophageal Cancer
Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC.
This trial is conducted in patients with unresectable locally advanced esophageal squamous cell carcinoma. The investigators plan to enroll 60 patients with unresectable locally advanced esophageal cancer in Tianjin cancer…
- Trial name
- NCT06452602
- Testing
- Induction immunochemotherapy followed by Adebrelimab plus concurrent chemoradiotherapy, Induction immunochemotherapy followed by concurrent chemoradiotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Rectal Cancer
A Trial of High Intensity Versus Low Intensity Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer
Neoadjuvant chemoradiotherapy (CRT) has been the standard therapy for local advanced rectal cancer. Pathological complete response (pCR) is an important prognostic factor for local control and survival.
- Trial name
- NCT01064999
- Testing
- Oxaliplatin, Capecitabine, Radiotherapy
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Fudan University
Colorectal Cancer
Radiation Therapy Plus Chemotherapy Followed by Surgery in Treating Patients With Locally Advanced Cancer of the Rectum
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00006366
- Testing
- fluorouracil, irinotecan hydrochloride, conventional surgery
- Where
- 235 sites in United States, Canada
- Sponsor
- Radiation Therapy Oncology Group
Pancreatic Cancer
Chemoradiation in Locally Advanced Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as fluorouracil and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00262951
- Testing
- recombinant interferon alfa, cisplatin, fluorouracil
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Locally Advanced Nasopharyngeal Carcinoma
Consolidation Nivolumab After Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma
The clinical efficacy of nivolumab for locally advanced nasopharyngeal carcinoma patients with residual disease after standard chemoradiotherapy is not known.
- Trial name
- NCT04910347
- Testing
- Nivolumab
- Where
- South Korea
- Volunteers
- 57 people
- Sponsor
- Yonsei University
Radiation Therapy Complication, Chemotherapeutic Toxicity
System for High-Intensity Evaluation During Radiotherapy
This quality improvement project will evaluate the implementation of a previously described intervention (twice per week on-treatment clinical evaluations) in a feasible fashion using a previously described machine learning…
- Trial name
- SHIELD-RT (NCT04277650)
- Testing
- Machine learning algorithm
- Where
- United States
- Volunteers
- 311 people
- Sponsor
- Duke University
Neoadjuvant Non-Small Cell Lung Cancer
Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma
The project is a Phase III, randomized, open-label, multicenter study in which approximately 36 patients with unresectable Stage III ALK positive Lung Adenocarcinoma will be randomized 1:1 to receive lorlatinib or…
- Trial name
- NCT06858410
- Testing
- lorlatinib, concurrent/sequential platinum-based chemoradiotherapy
- Volunteers
- 36 people
- Sponsor
- Guangdong Association of Clinical Trials
Head and Neck Neoplasms, Carcinoma, Squamous Cell
Postoperative Concurrent Chemoradiation for Head and Neck Cancer With Multiple Minor Risk
The purpose of this study is to determine the treatment outcome of postoperative concurrent chemoradiation for head and neck squamous cell carcinoma with multiple minor risks.
- Trial name
- NCT00937612
- Testing
- Radiotherapy
- Where
- 3 sites in Taiwan
- Volunteers
- 10 people
- Sponsor
- Chang Gung Memorial Hospital
Cervix Cancer
Alendronate to Reduce Pelvic Insufficiency Fractures in Cervical Cancer Patients Undergoing Chemoradiation
Primary Objective Proof of concept: To evaluate the efficacy of alendronate in preventing pelvic insufficiency fractures (PIFs) in cervical cancer patients treated with chemo-radiotherapy over the short and long term.
- Trial name
- NCT07245381
- Testing
- Alendronate 70mg weekly
- Volunteers
- 65 people
- Sponsor
- Dr. Itay GoorAryeh
Endometrial Cancer
Modality of Adjuvant Radiotherapy and Chemotherapy for Stage Ⅲ Endometrial Cancer
Endometrial cancer is the most common gynecological malignancy affecting women's health. About 15% of the patients will have local late disease (stage III) with high risk of recurrence and tumor related mortality.
- Trial name
- NCT04453904
- Testing
- sequential radiochemotherapy in a "sanwich" mode
- Where
- China
- Volunteers
- 654 people
- Sponsor
- Peking University People's Hospital
Esophageal Cancer
Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC
A total of 120 patients with unresectable, locally advanced esophageal squamous cell carcinoma patients will be enrolled in this study and randomly divided into two groups.
- Trial name
- NCT07733830
- Testing
- Adebrelimab, Nab paclitaxel, Carboplatin
- Where
- 7 sites in China
- Volunteers
- 120 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
NSCLC
Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC
This is a phase II trial of neoadjuvant and adjuvant atezolizumab with or without tiragolumab in conjunction with chemoradiotherapy for unresectable stage III NSCLC.
- Trial name
- NCT05798663
- Testing
- Atezolizumab, Tiragolumab
- Where
- 15 sites in United States
- Volunteers
- 178 people
- Sponsor
- Alliance Foundation Trials, LLC.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.